Valuation: Bonesupport Holding AB

Market Cap 14.58B 1.54B 1.33B 1.24B 1.14B 2.14B 147B 2.18B 5.72B 73.32B 5.77B 5.64B 244B P/E 2026 *
47x
P/E 2027 * 28.9x
Enterprise Value 14.03B 1.48B 1.28B 1.2B 1.09B 2.06B 141B 2.09B 5.5B 70.53B 5.55B 5.43B 235B EV / Sales 2026 *
9.4x
EV / Sales 2027 * 6.9x
Free-Float
85.24%
Yield 2026 *
0.66%
Yield 2027 * 0.97%
1 day+17.06%
1 week+17.06%
Current month+17.06%
1 month+12.06%
3 months-4.08%
6 months+26.21%
Current year+21.14%
1 week 23.3
Extreme 23.3
25
1 month 20.48
Extreme 20.485
25
Current year 19
Extreme 19
28.57
1 year 18.57
Extreme 18.57
33.7
3 years 15.74
Extreme 15.74
35
5 years 3.83
Extreme 3.83
35
10 years 3.83
Extreme 3.83
35
Manager TitleAgeSince
Chief Executive Officer 49 01/09/2025
Director of Finance/CFO 63 01/11/2018
Chief Operating Officer 51 01/12/2021
Director TitleAgeSince
Director/Board Member 68 01/01/2010
Chairman 70 15/12/2016
Chairman 71 14/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
+31.53%+17.06% - - 1.55B
+3.02%+6.43%+43.53%+1.90% 78.32B
+0.84%+10.26%-0.15%+27.24% 51.1B
+0.90%+1.67%+22.01%+176.54% 49.18B
+2.92%+8.18%-48.46%-49.18% 44.71B
-0.39%+2.63%+58.51%-23.02% 30.72B
+0.82%+2.63%+55.06%+85.54% 24.44B
+1.08%+8.47%+128.98%-40.36% 23.62B
+0.46%+13.14%+6.63%+202.17% 21.05B
-0.62%+3.30%+65.10%+114.68% 16.61B
Average +2.70%+4.26%+36.80%+55.06% 37.75B
Weighted average by Cap. +1.48%+4.34%+28.63%+43.01%

Financials

2026 *2027 *
Net sales 1.49B 157M 136M 127M 116M 219M 14.99B 222M 585M 7.5B 590M 577M 24.98B 1.99B 209M 181M 169M 155M 292M 19.97B 296M 780M 9.99B 786M 769M 33.27B
Net income 319M 33.64M 29.12M 27.22M 24.87M 46.88M 3.21B 47.61M 125M 1.6B 126M 124M 5.35B 511M 53.87M 46.64M 43.59M 39.84M 75.08M 5.14B 76.25M 201M 2.57B 202M 198M 8.56B
Net Debt -555M -58.45M -50.6M -47.3M -43.23M -81.46M -5.57B -82.73M -218M -2.79B -219M -215M -9.29B -874M -92.07M -79.7M -74.5M -68.09M -128M -8.78B -130M -343M -4.39B -346M -338M -14.63B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
171
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
221.40SEK
Average target price
358.25SEK
Spread / Average Target
+61.81%

Quarterly revenue - Rate of surprise